A Digitally-Enabled System for Precision Assessment and Intervention of Disability Risk in Older Adults
Condition(s) studied
Investigational drug(s) / intervention(s)
Risk Assessment of Disability and Precision Intervention: Implement a digital platform for elderly disability risk intervention to conduct comprehensive, multi-scenario intelligent assessments, dynamic monitoring, and targeted interventions for disability risks.
Study summary
1. Identify the primary risk factors for disability in older adults through multi-dimensional risk factor screening.
2. Develop a risk stratification model for disability in older adults by integrating outcome indicators and temporal characteristics, and construct an intelligent early warning model to enable automated assessment and monitoring of disability risk.
3. Establish key digital technologies for early warning and prevention of disability risk in older adults, and develop a whole-process digital intervention platform incorporating a decision support system for disability prevention management.
4. Create a digitally empowered hospital-community-household collaborative system for precise assessment and intervention of disability risk in older adults, achieving data-driven whole-process active disability management. The system will be demonstrated and evaluated in communities with diverse characteristics across urban, county, and rural settings.
Eligibility
Primary outcome measure(s)
- SPPB(SHORT PHYSICAL PERFORMANCE BATTERY PROTOCOL) — At baseline, 3 months after intervention, and 6 months after intervention
the range of score is 0-12, and the higher scores mean a better outcome.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The Second Affiliated Hospital of Medical College of Zhejiang University | Hangzhou | Zhejiang | Recruiting |
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07508813 on ClinicalTrials.gov ↗ ← All trials in China